Print Page   |   Contact Us   |   Sign In   |   Join
News and Press: Member Organization News

Esperion Reports Promising Phase 2 Results for Cholesterol Lowering Drug

Friday, October 14, 2016   (0 Comments)
Posted by: Kate Oesterle
Share |

Ann Arbor pharma company plans to start final Phase 3 trials later this year

 

Ann Arbor-based Esperion Therapeutics Inc. (Nasdaq: ESPR), a pharmaceutical company focused on developing oral therapies for the treatment of patients with elevated levels of low density lipoprotein cholesterol (LDL-C), announced Thursday that it achieved promising results of Phase 2 human trials and is moving on to Phase 3 trials, the last trials needed before commercialization.

The Phase 2 trials showed that bempedoic acid, the company's lead drug candidate, reduced elevated LDL-C levels in patients with hypercholesterolemia, including patients whose LDL levels are inadequately responding to current lipid-modifying therapies such as the statin class of drugs.

Read full article.


Creating Value
by delivering business-critical resources & bottom line savings
Building Networks
by connecting Michigan's bio-industry one member at a time
Growing Talent
by creating opportunities that develop people & build organizations
Membership Software Powered by YourMembership  ::  Legal